Alkermes plc vs Xenon Pharmaceuticals Inc.: Strategic Focus on R&D Spending

R&D Spending: Alkermes vs Xenon - A Decade of Innovation

__timestampAlkermes plcXenon Pharmaceuticals Inc.
Wednesday, January 1, 2014775300011768000
Thursday, January 1, 2015401900015152000
Friday, January 1, 2016230100019828000
Sunday, January 1, 2017723200025573000
Monday, January 1, 20186889500023634000
Tuesday, January 1, 20195281600038845000
Wednesday, January 1, 2020194600050523000
Friday, January 1, 2021102000075463000
Saturday, January 1, 2022393842000105767000
Sunday, January 1, 2023270806000167512000
Monday, January 1, 2024245326000
Loading chart...

In pursuit of knowledge

Strategic Focus on R&D Spending: Alkermes plc vs Xenon Pharmaceuticals Inc.

In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alkermes plc and Xenon Pharmaceuticals Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Alkermes plc's R&D expenses surged by over 3,400%, peaking in 2022 with a remarkable 394 million USD. This reflects a strategic pivot towards aggressive innovation. In contrast, Xenon Pharmaceuticals Inc. maintained a steady increase, with a notable 42% rise in 2023 compared to the previous year, reaching 168 million USD. This consistent growth underscores their commitment to sustainable innovation. The data highlights how these companies are navigating the evolving pharmaceutical landscape, with Alkermes focusing on rapid expansion and Xenon on steady growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025